Skip to main content
SpringerLink
Log in

Drug Interactions in HIV: Protease and Integrase Inhibitors

  • Chapter
  • First Online:
Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions

Part of the book series: Infectious Disease ((ID))

Abstract

Significant advances in HIV treatment have transpired in recent years. Current antiretroviral therapies (ARTs) are highly efficacious, well-tolerated, and often administered in fixed-dose combination products which allow for one pill once daily administration. In the United States, guidelines for the initial treatment of HIV recommend two nucleoside/tide reverse transcriptase inhibitors plus either a protease inhibitor (PIs; ritonavir-boosted darunavir) or integrase inhibitor (INIs; dolutegravir, elvitegravir, raltegravir). PIs participate in a number of cytochrome P450 and transporter-mediated drug interactions. INIs have a reduced potential for drug interactions compared with older ART therapies but are not devoid of interactions. This class is also being investigated as part of nucleos(t)ide analog-sparing regimens and as long-acting injectables for HIV treatment and prevention. This chapter reviews the pharmacology and drug interaction potential of PIs and INIs used in the treatment of HIV with summary tables to guide patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents (2016) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed 12/21/16

  2. www.hiv-druginteractions.org

  3. http://arv.ucsf.edu/insite?page=ar-00-02&post=7

  4. www.medscape.com

  5. van Heeswijk RP, Veldkamp A, Mulder JW et al (2001) Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6:201–229

    PubMed  Google Scholar 

  6. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG (2005) Vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33(11):1729–1739

    Article  CAS  PubMed  Google Scholar 

  7. Mouscadet J-F, Tchertanov L (2009) Raltegravir: molecular basis of its mechanism of action. Eur J Med Res 14(Suppl 3):5–16

    Article  PubMed  PubMed Central  Google Scholar 

  8. Brainard DM, Friedman EJ, Jin B et al (2011) Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 51:422–427

    Article  CAS  PubMed  Google Scholar 

  9. Ramanathan S, Mathias AA, German P et al (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50:229–244

    Article  CAS  PubMed  Google Scholar 

  10. Ramanathan S, Wright M, West S, et al. Pharmacokinetics, metabolism and excretion of ritonavir-boosted GS-9137(elvitegravir). 8th International Workshop on clinical pharmacology of HIV therapy. April 16–18, 2007, Budapest, Abstract 30

    Google Scholar 

  11. Lepist E-I, Phan TK, Roy A et al (2012) Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 56:5409–5413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) package insert (2016) Gilead Sciences Inc., Foster City

    Google Scholar 

  13. Ramanathan S, Wang H, Szwarcberg J, Kearney BP. Safety/tolerability, pharmacokinetics, and boosting of twice-daily cobicistat administered alone or in combination with Darunavir or Tipranavir. 13th HIV clinical pharmacology workshop Apr 16–18 2012, Barcelona

    Google Scholar 

  14. German P, West S, Hui J, et al. Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin. 9th International Workshop on clinical pharmacology of HIV therapy. April 7–9, 2008, New Orleans, Abstract 19

    Google Scholar 

  15. Vitekta (elvitegravir) package insert (2015) Gilead Sciences Inc, Foster City

    Google Scholar 

  16. Cottrell ML, Hadzic T, Kashuba AD (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52:981–994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dooley KE, Sayre P, Borland J et al (2013) Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 62:21–27

    Article  CAS  PubMed  Google Scholar 

  18. Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D et al (2014) Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol 70:1173–1179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Song I, Borland J, Min S et al (2011a) Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 55:3517–3521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Song I, Borland J, Chen S et al (2011b) Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol 72:103–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39(6):1070–1078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Buss N, Snell P, Bock J, Hsu A, Jorga K (2001) Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 52(3):255–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, Bricaire F, Duvivier C, Calvez V, Peytavin G, Katlama C (2003) Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 17(2):209–214

    Article  CAS  PubMed  Google Scholar 

  24. Collin F, Chêne G, Retout S, Peytavin G, Salmon D, Bouvet E, Raffi F, Garraffo R, Mentré F, Duval X, ANRS CO8 Aproco-Copilote Study Group (2007) Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit 29(2):164–170

    Article  CAS  PubMed  Google Scholar 

  25. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, Jaillon P, Rozenbaum W (2003) High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47(3):986–990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tybost (cobicistat) package insert (2016) Gilead Sciences Inc, Foster City

    Google Scholar 

  27. Marzolini C, Gibbons S, Khoo S, Back D (2016) Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother 71:1755–1758

    Article  CAS  PubMed  Google Scholar 

  28. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-EVG with atazanavir, rosuvastatin or rifabutin. 13th International Workshop on clinical pharmacology of HIV therapy. April 16–18, 2012, Barcelona, Abstract O_03

    Google Scholar 

  29. Mathias A, Liu HC, Warren D, Sekar V, Kearney BP. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir. 11th International Workshop on clinical pharmacology and HIV therapy. April 7–9, 2010. Sorrento. Abstract 28

    Google Scholar 

  30. Luber A, Garg V, Gharakhanian S, et al. Survey of medications used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. Poster #206. 7th International Congress on Drug Therapy in HIV Infection; 14–18 November 2004

    Google Scholar 

  31. Reyataz [package insert] (2004) Bristol-Myers Squibb Company, Princeton

    Google Scholar 

  32. Isentress (raltegravir) package insert (2017) Merck & Co., Whitehouse Station

    Google Scholar 

  33. Kiser JJ, Bumpass JB, Meditz AL et al (2010) Effect of antacids on the pharmacokinetics of Raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 54:4999–5003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Moss DM, Siccardi M, Murphy M et al (2012) Divalent metals and pH alter raltegravir disposition In Vitro. Antimicrob Agents Chemother 56:3020–3026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tivicay (dolutegravir) package insert (2016) Viiv Healthcare, Research Triangle Park

    Google Scholar 

  36. Cohn SE, Park JG, Watts DH et al (2007) Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 81(2):222–227

    Article  CAS  PubMed  Google Scholar 

  37. Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI (2003) Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 43(4):414–422

    Article  CAS  PubMed  Google Scholar 

  38. Wiggins BS, Lamprecht DG, Page RL et al (2017) Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs 17:375

    Article  PubMed  Google Scholar 

  39. Busti AJ, Bain AM, Hall RG et al (2008) Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardovasc Pharmacol 51:605–610

    Article  CAS  Google Scholar 

  40. Fichtembaum C, Samineni D, Moore E, et tal. Darunavir/ritonavir incresaes rosuvastatin concentrations but does not alter lipid-lowering effect in healthy volunteers [poster WePE0101]. 18th international AIDS conference, July 18–23, 2010; Vienna

    Google Scholar 

  41. Hoody DW, Kiser JJ, et al. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin [poster #564]. 14th conference on retroviruses and opportunistic infections; 2007 Feb 25–28; Los Angeles

    Google Scholar 

  42. Koteff J, Borland J, Chen S et al (2013) A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 75(4):990–996

    Article  CAS  PubMed  Google Scholar 

  43. Song IH, Zong J, Borland J et al (2016) The effect of Dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr 72:400–407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Yombi JC, Pozniak A, Boffito M et al (2014) Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS 28(5):621–632

    Article  CAS  PubMed  Google Scholar 

  45. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S et al (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, noninferiority trial. Lancet 379:2429–2243

    Article  CAS  PubMed  Google Scholar 

  46. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D et al (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:2439–2448

    Article  CAS  PubMed  Google Scholar 

  47. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) package insert (2017) Gilead Sciences Inc, Foster City

    Google Scholar 

  48. Descovy (emtricitabine/tenofovir alafenamide) package insert (2017) Gilead Sciences Inc, Foster City

    Google Scholar 

  49. Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG (2017) Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine (Baltimore) 96(36):e8046

    Article  Google Scholar 

  50. German P, Liu HC, Szwarcberg J et al (2012) Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 61:32–40

    Article  CAS  PubMed  Google Scholar 

  51. Milburn J, Jones R, Levy JB (2017) Renal effects of novel antiretroviral drugs. 2017. Nephrol Dial Transplant 32(3):434–439

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology, ViiV Healthcare, Research Triangle Park, NC, USA

    Parul Patel

  2. University of Southern California, School of Pharmacy, Los Angeles, CA, USA

    Stan Louie

Authors
  1. Parul Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stan Louie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Parul Patel .

Editor information

Editors and Affiliations

  1. College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA

    Manjunath P. Pai

  2. Department of Pharmaceutical Sciences, Skagg School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA

    Jennifer J. Kiser

  3. Division of Pharmacy Practice and Administration, UMKC School of Pharmacy at MSU, Springfield, Missouri, USA

    Paul O. Gubbins

  4. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

    Keith A. Rodvold

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patel, P., Louie, S. (2018). Drug Interactions in HIV: Protease and Integrase Inhibitors. In: Pai, M., Kiser, J., Gubbins, P., Rodvold, K. (eds) Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Infectious Disease. Humana Press, Cham. https://doi.org/10.1007/978-3-319-72416-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72416-4_7

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-72415-7

  • Online ISBN: 978-3-319-72416-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation